loading
전일 마감가:
$16.80
열려 있는:
$16.82
하루 거래량:
18,930
Relative Volume:
0.57
시가총액:
$31.39M
수익:
-
순이익/손실:
$-4.85M
주가수익비율:
-56.00
EPS:
-0.31
순현금흐름:
$-3.95M
1주 성능:
+7.29%
1개월 성능:
-5.96%
6개월 성능:
+15.04%
1년 성능:
+168.83%
1일 변동 폭
Value
$16.80
$17.50
1주일 범위
Value
$15.85
$17.50
52주 변동 폭
Value
$5.70
$22.90

Cadrenal Therapeutics Inc Stock (CVKD) Company Profile

Name
명칭
Cadrenal Therapeutics Inc
Name
전화
904-300-0701
Name
주소
822 A1A NORTH, PONTE VEDRA
Name
직원
4
Name
트위터
Name
다음 수익 날짜
Name
최신 SEC 제출 서류
Name
CVKD's Discussions on Twitter

CVKD을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Biotechnology icon
CVKD
Cadrenal Therapeutics Inc
17.36 31.39M 0 -4.85M -3.95M -0.31
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
496.49 122.76B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
610.86 61.38B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
620.97 36.37B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
254.85 30.12B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
249.46 24.70B 3.81B -644.79M -669.77M -6.24

Cadrenal Therapeutics Inc Stock (CVKD) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2023-12-18 개시 Noble Capital Markets Outperform

Cadrenal Therapeutics Inc 주식(CVKD)의 최신 뉴스

pulisher
Apr 24, 2025

Cadrenal Therapeutics (NASDAQ:CVKD) Shares Up 0.8% – Here’s Why - Defense World

Apr 24, 2025
pulisher
Apr 22, 2025

Trading (CVKD) With Integrated Risk Controls - news.stocktradersdaily.com

Apr 22, 2025
pulisher
Apr 17, 2025

Cadrenal Therapeutics to Present at Inaugural Centri Capital Conference at Nasdaq - BioSpace

Apr 17, 2025
pulisher
Apr 17, 2025

Cadrenal Therapeutics Reveals Latest Phase 3 Anticoagulant Progress at Exclusive Nasdaq Conference - Stock Titan

Apr 17, 2025
pulisher
Apr 17, 2025

Cadrenal Therapeutics IncFiles Prospectus Supplement For $2.17 Million ATM Offering - marketscreener.com

Apr 17, 2025
pulisher
Apr 06, 2025

Is Cadrenal Therapeutics (NASDAQ:CVKD) In A Good Position To Deliver On Growth Plans? - Yahoo

Apr 06, 2025
pulisher
Apr 05, 2025

When (CVKD) Moves Investors should Listen - news.stocktradersdaily.com

Apr 05, 2025
pulisher
Apr 03, 2025

Cadrenal Therapeutics Participates in Key Medical and Business Development Conferences - BioSpace

Apr 03, 2025
pulisher
Apr 03, 2025

Cadrenal Takes Center Stage: Key Executives to Showcase Novel Anticoagulant at Industry-Leading Events - Stock Titan

Apr 03, 2025
pulisher
Apr 03, 2025

Q1 Earnings Estimate for CVKD Issued By Zacks Small Cap - Defense World

Apr 03, 2025
pulisher
Mar 16, 2025

(CVKD) Trading Advice - Stock Traders Daily

Mar 16, 2025
pulisher
Mar 14, 2025

Altimmune to put its incretin into addiction trials; Tarsus aims to raise $125M - Endpoints News

Mar 14, 2025
pulisher
Mar 14, 2025

Cadrenal Therapeutics Advances Tecarfarin Development in 2024 - TipRanks

Mar 14, 2025
pulisher
Mar 13, 2025

Cadrenal Therapeutics Reports Full Year 2024 Results - TradingView

Mar 13, 2025
pulisher
Mar 13, 2025

Cadrenal Therapeutics, Inc. SEC 10-K Report - TradingView

Mar 13, 2025
pulisher
Mar 13, 2025

Cadrenal Therapeutics Reports Full Year 2024 Results, Business Highlights, and Path Forward for Clinical Advancement of Tecarfarin - Bluefield Daily Telegraph

Mar 13, 2025
pulisher
Mar 13, 2025

Cadrenal Secures FDA Orphan Drug Status and Abbott Partnership for Breakthrough Phase 3 Trial - StockTitan

Mar 13, 2025
pulisher
Mar 07, 2025

CVKD: Collaborating with Abbott for Pivotal Phase 3 Trial - Research Tree

Mar 07, 2025
pulisher
Mar 05, 2025

(CVKD) Technical Pivots with Risk Controls - Stock Traders Daily

Mar 05, 2025
pulisher
Mar 05, 2025

Cadrenal and Abbott sign agreement for LVAD trial of tecarfarin - Yahoo Finance

Mar 05, 2025
pulisher
Mar 04, 2025

Cadrenal Therapeutics teams with Abbott inTECH-LVAD trial - TipRanks

Mar 04, 2025
pulisher
Mar 04, 2025

Abbott Laboratories (NYSE:ABT) Partners With Cadrenal Therapeutics For TECH-LVAD Trial In Growing US$2B LVAD Market - Yahoo Finance

Mar 04, 2025
pulisher
Mar 04, 2025

Cadrenal Therapeutics Announces Collaboration Agreement with Abbott in Support of Pivotal Study of Tecarfarin in Patients with HeartMate 3™ LVAD - BioSpace

Mar 04, 2025
pulisher
Mar 04, 2025

Cadrenal Therapeutics to Collaborate With Abbott on Trial of Heart Device Drug -March 04, 2025 at 08:53 am EST - Marketscreener.com

Mar 04, 2025
pulisher
Mar 04, 2025

Cadrenal Therapeutics Announces Collaboration Agreement With Abbott -March 04, 2025 at 08:14 am EST - Marketscreener.com

Mar 04, 2025
pulisher
Mar 03, 2025

Cadrenal Therapeutics (CVKD) Projected to Post Earnings on Monday - The AM Reporter

Mar 03, 2025
pulisher
Mar 03, 2025

Cadrenal Therapeutics (CVKD) Expected to Announce Earnings on Monday - Defense World

Mar 03, 2025
pulisher
Feb 26, 2025

CVKD stock hits 52-week high at $20.79 amid robust growth By Investing.com - Investing.com South Africa

Feb 26, 2025
pulisher
Feb 26, 2025

CVKD stock hits 52-week high at $20.79 amid robust growth - Investing.com India

Feb 26, 2025
pulisher
Feb 22, 2025

(CVKD) Trading Signals - Stock Traders Daily

Feb 22, 2025
pulisher
Feb 08, 2025

Cadrenal Therapeutics Announces New Chief Medical Officer in Recent SEC Filing - Defense World

Feb 08, 2025
pulisher
Feb 07, 2025

Biondi becomes managing partner at Flagship - BioCentury

Feb 07, 2025
pulisher
Feb 07, 2025

Cadrenal Therapeutics Appoints New Chief Medical Officer - TipRanks

Feb 07, 2025
pulisher
Feb 07, 2025

Clinical Trials News Live Feed - StockTitan

Feb 07, 2025
pulisher
Feb 06, 2025

Cadrenal Therapeutics appoints new chief medical officer - MSN

Feb 06, 2025
pulisher
Feb 06, 2025

Cadrenal Therapeutics appoints new chief medical officer By Investing.com - Investing.com UK

Feb 06, 2025
pulisher
Feb 06, 2025

Cadrenal Therapeutics Announces Chief Medical Officer Transition to Advance Clinical Development of Tecarfarin - Business Wire

Feb 06, 2025
pulisher
Feb 06, 2025

Former Amgen & AstraZeneca Executive Takes Helm of Revolutionary Anticoagulation Drug Development - Stock Titan

Feb 06, 2025
pulisher
Feb 05, 2025

Cadrenal Therapeutics to Present at BIO CEO & Investor Conference - BioSpace

Feb 05, 2025
pulisher
Feb 05, 2025

Revolutionary Warfarin Alternative Takes Center Stage: Cadrenal CEO to Unveil Latest Tecarfarin Data - StockTitan

Feb 05, 2025
pulisher
Jan 31, 2025

(CVKD) Investment Report - Stock Traders Daily

Jan 31, 2025
pulisher
Jan 23, 2025

Cadrenal Therapeutics (NASDAQ:CVKD) Trading 14.3% Higher – Time to Buy? - Defense World

Jan 23, 2025
pulisher
Jan 21, 2025

Ponte Vedra-based Cadrenal CEO Quang Pham talks biotech, funding - The Business Journals

Jan 21, 2025
pulisher
Jan 21, 2025

Learn to Evaluate (CVKD) using the Charts - Stock Traders Daily

Jan 21, 2025
pulisher
Jan 13, 2025

Ponte Vedra biotech firm opens the Nasdaq - The Business Journals

Jan 13, 2025
pulisher
Jan 10, 2025

(CVKD) Long Term Investment Analysis - Stock Traders Daily

Jan 10, 2025
pulisher
Jan 09, 2025

Cadrenal Therapeutics CEO to Present Breakthrough Anticoagulant at Lytham Healthcare Summit - StockTitan

Jan 09, 2025
pulisher
Jan 09, 2025

Cadrenal Therapeutics to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025 - BioSpace

Jan 09, 2025
pulisher
Jan 03, 2025

Short Interest in Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) Expands By 5.7% - Defense World

Jan 03, 2025
pulisher
Dec 31, 2024

Cadrenal Therapeutics Provides 2024 Year-End Company Update, Reinforcing Clinical Development Plan for Tecarfarin in LVAD and Other Rare Cardiovascular Indications - Business Wire

Dec 31, 2024
pulisher
Dec 22, 2024

AT&T (NYSE:T) Price Target Raised to $30.00 - Defense World

Dec 22, 2024

Cadrenal Therapeutics Inc (CVKD) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading
$20.63
price up icon 0.19%
$69.86
price up icon 0.24%
$32.54
price up icon 1.06%
$24.11
price up icon 2.75%
$104.00
price up icon 1.94%
biotechnology ONC
$249.46
price up icon 1.86%
자본화:     |  볼륨(24시간):